BT-062 demonstriert schnelle und vollständige Tumorremission in präklinischen Studien
. - Hohe Wirksamkeit gegen aggressive solide Tumore, z.B. humane Brust-, Pankreas-, Blasen und Lungenkarzinome in präk…
. - Hohe Wirksamkeit gegen aggressive solide Tumore, z.B. humane Brust-, Pankreas-, Blasen und Lungenkarzinome in präk…
Most people are aware of the essential role Vitamin D plays in maintaining strong bones and muscles however many people…
Aldevron is pleased to announce its participation in a new three year, €3.9 million research project to study the long-t…
NovImmune announced today that Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), initiated a First-in…
Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment; TecDAX) präsentierte heute erstmals mit der Ylanthia®-Biblioth…
InteRNA Technologies B.V., a drug discovery and development company engaged in the development of microRNA-based therape…
NovImmune gab heute bekannt, dass bei PBC Patienten eine Proof-of-Concept (PoC) Studie mit NI-0801, einem neutralisieren…
NovImmune announced today that a Proof-of-Concept (PoC) study with NI-0801, a fully human monoclonal antibody neutralizi…
NovAliX today announces that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapa…
. - Collaboration on up to three targets and two programs - Upfront payment of EUR 10 million upon deal execution -…